News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Daily News Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC Michael O'Riordan March 01, 2023
News Daily News REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD L.A. McKeown January 24, 2023
News Daily News UK’s NICE Recommends Lower-Risk Thresholds for Statin Therapy Michael O'Riordan January 20, 2023
News Daily News PCSK9 Inhibition Shows Promise for Severe COVID-19 in Pilot Trial Todd Neale January 18, 2023
News Daily News Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3 Michael O'Riordan January 16, 2023
News Daily News Effect of Intensive BP-Lowering on Cardiac Biomarkers Varies: SPRINT Analysis Todd Neale December 23, 2022
News Daily News Reduction in BP Drives Treatment Preference for Hypertensive Patients Michael O'Riordan December 20, 2022
News Daily News A Simple Nudge Moves the Needle on Statin Prescribing Michael O'Riordan December 02, 2022
News Daily News How Lp(a) Levels Compare With LDL-C in FH: Some Surprises Michael O'Riordan November 17, 2022
News Daily News Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results Todd Neale November 16, 2022
News Conference News AHA 2022 Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION Michael O'Riordan November 09, 2022
News Conference News AHA 2022 Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study Michael O'Riordan November 07, 2022
News Conference News AHA 2022 ‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE Michael O'Riordan November 06, 2022
News Conference News AHA 2022 In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE Todd Neale November 05, 2022
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Daily News SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes Michael O'Riordan October 18, 2022
News Daily News Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use L.A. McKeown October 05, 2022